Dutasteride

Dutasteride


 
Action  
Indications  
Contraindications  
Route/Dosage  
Interactions  
Lab Test Interferences  
Adverse Reactions  
Precautions
Patient Care Considerations  
Administration/Storage  
Assessment/Interventions  
Patient/Family Education

(Doo-TASS-teer-ide) Avodart Capsules: 0.5 mg Class: Androgen hormone inhibitor

 Action Inhibits the conversion of testosterone to 5-alpha-dihydrotestosterone, a potent androgen.

Absorption: Tmax is 2 to 3 hr; bioavailability is approximately 60%; administration with food decreased Cmax 10% to 15%.

Distribution: Vd is 300 to 500 L; highly protein bound.

Metabolism: Metabolized by CYP3A4.

Elimination: Mainly excreted in feces (approximately 5% as unchanged dutasteride and approximately 40% as metabolites). The t½ is approximately 5 wk.

 Indications Treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

 Contraindications Women; children; hypersensitivity to 5-alpha-reductase inhibitors or any component of the product.

 Route/Dosage

Adults: PO 0.5 mg once daily.

 Interactions

Cytochrome P450 3A4 inhibitors (eg, cimetidine, ciprofloxacin, diltiazem, ketoconazole, ritonavir, verapamil): Plasma concentrations of dutasteride may be elevated, increasing the risk of side effects.

 Lab Test Interferences Decreased prostate-specific antigen levels.

 Adverse Reactions

GU: Impotence; decreased libido; ejaculation disorder; gynecomastia.

 Precautions

Pregnancy: Category X. Lactation: Undetermined. Children: Safety and efficacy not established. Hepatic impairment: Use with caution. Obstructive uropathy: Carefully monitor patients with large residual urine volume or severely diminished urinary flow.


PATIENT CARE CONSIDERATIONS

 Administration/Storage

  • Not for use in women.
  • Do not handle dutasteride capsules if pregnant or possibly pregnant.
  • Women who are not pregnant should use caution whenever handling dutasteride capsules. If contact is made with leaking capsules, wash the contacted area immediately with soap and water.
  • Administer as prescribed once daily without regard to meals.
  • Swallow capsules whole. Do not crush, cut, or chew.
  • Do not use capsules that are cracked or leaking.
  • Store at controlled room temperature (59° to 86°F). Protect from light.

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of liver disease.
  • Ensure that patient has had complete physical examination to rule out causes of urinary tract symptoms other than BPH.
  • Ensure that baseline PSA level is determined before starting therapy and periodically thereafter during therapy.
  • Monitor urine volume and frequency for evidence of improvement in symptoms.

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to read the “Patient Information” leaflet before starting dutasteride and with each refill.
  • Advise patient that prescribed dose is to be taken once daily without regard to meals and to try to take the dose at about the same time each day.
  • Advise patient that if a dose is missed to take as soon as remembered but to never take 2 doses the same day.
  • Advise patient that drug does not work immediately and that it may take 3 to 6 mo to experience maximum benefit.
  • Advise patient that ejaculate volume may be decreased during treatment but that this decrease does not interfere with normal sexual function.
  • Instruct patient to not stop taking dutasteride when symptoms have improved.
  • Caution patient that women who are or may be pregnant should not handle the medication because of risk of absorption though the skin and risk to developing male fetus.
  • Caution patient that a woman who is not pregnant can handle the capsules with caution but if contact is made with a leaking capsule to wash the contacted area immediately with soap and water.
  • Advise patient that impotence, decreased libido, and ejaculation disorder may occur with therapy but that these symptoms should lessen as treatment continues.
  • Advise patient against donating blood for at least 6 mo following discontinuation of therapy to prevent pregnant women from receiving dutasteride through a blood transfusion.
  • Instruct patient to not take any prescription or OTC medications or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests will be required to monitor therapy and to keep appointments.


Справочник препаратов (англ.) / D

Инфекционные болезни для всех
Женское здоровье
Инфекционные заболевания
Туберкулез
Хирургические болезни
Акушерство
Гинекология
Глазные болезни
Болезни уха, горла, носа
Стоматология
Кожные болезни
Венерические заболевания
Нервные болезни
Психические болезни
Детские болезни
Первая помощь
Хирургические болезни
Острые отравления
Лекарственные средства
Лабораторные анализы
Современные методы исследования
Уход за больными
Физио-терапевтические процедуры
Диетическое питание
Санаторно курортное лечение
Внутренние болезни

Это интересно